Characterizing the role of CSDE1 as a critical co-factor for VSV replication.
Characterizing the role of CSDE1 as a critical co-factor for VSV replication.
批准号:
10650485
负责人:
Richard G. Vile
金额:
$40.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-20 至 2028-02-29
关键词:
2019-nCoVAffectAntigensBinding SitesCell CommunicationCellsClonalityCodeComplementConsensusCytolysisDataDevelopmentDominant-Negative MutationEvolutionExposure toGenesGoalsHistologicHumanHuman papillomavirus 16 E1 proteinImmuneIn VitroInduced MutationIntercistronic RegionMediatingMediatorMusMutateMutationOncolyticPathway interactionsPhenotypePlayPoint MutationProteinsResistanceRoleShockTYRP1 geneTestingTimeTreatment FailureTumor AntigensVaccinationVaccinesVesicular stomatitis Indiana virusViralViral GenomeVirusVirus DiseasesVirus Replicationcofactorfitnessimmunogenicimprintimprovedin vivoin vivo Modelloss of functionmutantneoplastic cellnoveloncolysisoncolytic Vesicular Stomatitis Virusoncolytic virotherapypressurepreventscreeningtranscriptome sequencingtumorviral fitnessvirus identification
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
We have repeatedly observed that cells acquire the ability to escape from viral replication/lysis upon long-term
low-level exposure to Vesicular Stomatitis Virus (VSV). Whilst investigating the mechanisms associated with
escape, we showed that APOBEC3B is a major effector of mutational plasticity in cells which evade viral
replication/therapies including VSV. RNAseq of cells which escaped VSV identified ~300 coding mutations
with APOBEC3B signatures, some of which we hypothesized would directly affect the ability of the virus to
replicate within target cells. Of these mutations, a single C-T point mutation in the Cold Shock Domain
Containing E1 (CSDE1) gene (CSDE1C-T), which generates a mutant CSDE1 protein CSDE15P-S, was
expressed at high clonality in both human and murine cells, of different histological types, which became
resistant to VSV. These data show, for the first time to our knowledge, that CSDE1 plays a highly significant
role in replication of, and oncolysis by, VSV. We also observed that VSV can co-evolve to complement cellular
mutations such as CSDE1C-T. Thus, forced evolution of wild type VSV through CSDE15P-S cells allowed us to
track the emergence of a mutant virus VSV-IFNß-IGR P/MC-U. This virus contained a highly specific mutation
in the Intergenic region between the P and M genes of VSV (IGR P/MC-U) (located in the only perfect
consensus binding site for CSDE1 in the VSV genome) and completely rescued high level replication of virus
in cells expressing mutant CSDE15P-S. On the basis of these data, here we will test our overarching hypothesis
that CSDE1 is a critical mediator of the replication of VSV; that mutation in CSDE1, such as at CSDE1C-T,
allows for target cell escape from replication of VSV; and that VSV can evolve compensatory mutations to
recover replication fitness in CSDE1(C-T)-mutated cells. To test this hypothesis, we have formulated four
Specific Aims in which we will: (Aim 1) define how CSDE1 mediates replication of VSV, and how mutations in
CSDE1 are critically associated with escape from VSV; (Aim 2) understand how the IGR P/MC-U mutation in
VSV complements CSDE15P-S; (Aim 3) track the induction of the IGR P/MC-U mutation as the virus undergoes
strong selective pressures against its replication and identify the cellular anti-viral mutational pathways which
imprint mutational signatures onto VSV genomes; and (Aim 4) exploit our discovery of CSDE1 as a critical co-
factor for VSV replication to generate CSDE1-expressing VSV with enhanced efficacy as both vaccination and
oncolytic platforms. Overall, these studies will have significant impact in understanding VSV/host cell
interactions, in defining pathways by which viruses can usurp anti-viral mutagenic pathways to seed escape-
competent quasi species and will inform development of novel, improved VSV for vaccination and oncolysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Re-purposing Oncolytic Virotherapy to Re-invigorate CAR T Cell Therapy for Solid Tumors.
-
批准号:10578864
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2022
-
负责人:Richard G. Vile
-
依托单位:
Novel Strategies to Treat Diffuse Midline Glioma with CAR T Cell Therapy
-
批准号:10284722
-
项目类别:
-
资助金额:$22.3万
-
财政年份:2021
-
负责人:Richard G. Vile
-
依托单位:
Novel Strategies to Treat Diffuse Midline Glioma with CAR T Cell Therapy
-
批准号:10412129
-
项目类别:
-
资助金额:$18.21万
-
财政年份:2021
-
负责人:Richard G. Vile
-
依托单位:
Project 4: Immunovirotherapy
-
批准号:10468832
-
项目类别:
-
资助金额:$25.32万
-
财政年份:2018
-
负责人:Richard G. Vile
-
依托单位:
Project 4: Immunovirotherapy
-
批准号:10006086
-
项目类别:
-
资助金额:$31.58万
-
财政年份:2018
-
负责人:Richard G. Vile
-
依托单位:
Project 4: Immunovirotherapy
-
批准号:10251135
-
项目类别:
-
资助金额:$29.86万
-
财政年份:2018
-
负责人:Richard G. Vile
-
依托单位:
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
-
批准号:8687777
-
项目类别:
-
资助金额:$26.39万
-
财政年份:2014
-
负责人:Richard G. Vile
-
依托单位:
Enhancing Therapy of Primary and Recurrent Tumors With Systemic Oncolytic Virus
-
批准号:9047245
-
项目类别:
-
资助金额:$26.39万
-
财政年份:2014
-
负责人:Richard G. Vile
-
依托单位:
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
-
批准号:8387981
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2009
-
负责人:Richard G. Vile
-
依托单位:
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
-
批准号:7993072
-
项目类别:
-
资助金额:$27.37万
-
财政年份:2009
-
负责人:Richard G. Vile
-
依托单位:
Flow
-
批准号:7945044
-
项目类别:
-
资助金额:$12.94万
-
财政年份:2009
-
负责人:Richard G. Vile
-
依托单位:
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
-
批准号:8196780
-
项目类别:
-
资助金额:$27.37万
-
财政年份:2009
-
负责人:Richard G. Vile
-
依托单位:
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
-
批准号:7576024
-
项目类别:
-
资助金额:$28.22万
-
财政年份:2009
-
负责人:Richard G. Vile
-
依托单位:
Enhancing Systemic Delivery of Oncolytic Viruses for Cancer Therapy
-
批准号:7752520
-
项目类别:
-
资助金额:$28.22万
-
财政年份:2009
-
负责人:Richard G. Vile
-
依托单位:
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm
-
批准号:8260203
-
项目类别:
-
资助金额:$30.41万
-
财政年份:2008
-
负责人:Richard G. Vile
-
依托单位:
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm
-
批准号:8067941
-
项目类别:
-
资助金额:$30.41万
-
财政年份:2008
-
负责人:Richard G. Vile
-
依托单位:
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm
-
批准号:7644431
-
项目类别:
-
资助金额:$31.35万
-
财政年份:2008
-
负责人:Richard G. Vile
-
依托单位:
Autoimmunity and anti tumor immunity outside of the melanocyte/melanoma paradigm
-
批准号:7848918
-
项目类别:
-
资助金额:$31.35万
-
财政年份:2008
-
负责人:Richard G. Vile
-
依托单位:
T Cell Based Carriers for In Vivo Gene Therapy of Cancer
-
批准号:6965589
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2005
-
负责人:Richard G. Vile
-
依托单位:
T Cell Based Carriers for In Vivo Gene Therapy of Cancer
-
批准号:7229472
-
项目类别:
-
资助金额:$27.9万
-
财政年份:2005
-
负责人:Richard G. Vile
-
依托单位:
海外基金